Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05308264 · ClinicalTrials.gov registry record · Phase 1
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
A Phase 1 study of Low Risk Myelodysplastic Syndromes, sponsored by Rigel Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
- 15
- Study locations
NCT05308264: Recruiting Phase 1 study of Low Risk Myelodysplastic Syndromes, sponsored by Rigel Pharmaceuticals.
NCT05308264 is a Phase 1 study of Low Risk Myelodysplastic Syndromes that is actively recruiting participants, run by Rigel Pharmaceuticals. The registered enrollment target is 86 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% higher). The trial reports 15 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05308264, a Phase 1 study of Low Risk Myelodysplastic Syndromes, is actively recruiting participants, sponsored by Rigel Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
- 15
- Study locations
Study Summary
Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
Primary Outcome
* Incidence of adverse events (AEs) * Incidence of discontinuation or interruptions of R289 due to AEs * Incidence of dose limiting toxicities (DLTs)
Conditions Studied
Interventions
- DRUG R906289 Monosodium (R289 Na)
Study Locations (15)
California
- University of California, Los Angeles - Los Angeles
- University of California, Irvine - Orange
- Stanford Cancer Institute - Palo Alto
Florida
- University of Miami - Miami
- Mount Sinai Medical Center - Miami Beach
New Jersey
- Oncology Clinical Research Referral Office - Hackensack
- Rutgers Cancer Institute of New Jersey - New Brunswick
Ohio
- Cleveland Clinic - Cleveland
- The Ohio State University Comprehensive Cancer Center - Columbus
Texas
- University of Texas, Southwestern - Dallas
- MD Anderson Cancer Center - Houston
Missouri
- WashU Medicine - St Louis
New York
- Ichan School of Medicine at Mount Sinai - New York
North Carolina
- Duke Cancer Institute - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2022-09-12 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT05308264 shows while recruiting
NCT05308264 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% higher).
The record links to 1 condition, with Low Risk Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which R906289 Monosodium (R289 Na) is the first listed.
NCT05308264 lists 15 locations in 9 states (California, Florida, New Jersey).
Frequently Asked Questions
What is clinical trial NCT05308264 about?
NCT05308264 is a clinical study titled "Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)". Phase 1b Study of R289 in Patients with Lower-risk Myelodysplastic Syndromes (LR MDS)
What is the current status of trial NCT05308264?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2022-09-12. Estimated completion is 2026-12.
What conditions does trial NCT05308264 study?
This clinical trial studies the following conditions: Low Risk Myelodysplastic Syndromes.
What interventions are being tested in trial NCT05308264?
The interventions under investigation include: R906289 Monosodium (R289 Na) (DRUG).
Who is sponsoring clinical trial NCT05308264?
This trial is sponsored by Rigel Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05308264 being conducted?
This trial has 15 study locations across California, Florida, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05308264's enrollment target sits among peer trials
86 653rd of 2000 higher than 1,345 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI